FDA Approves Mimrylo (Rusfertide), First Hepcidin Mimetic for Polycythemia Vera
The FDA has cleared Mimrylo (rusfertide) for adults with polycythemia vera, calling it the first drug of its kind for the rare blood disorder.
Read more
TREASURE GLOBAL (TGL) Unit Joins $367M, 360 MW Malaysian Solar Farm Project
Tadaa Technology will supply the AI backbone for a 1,000-acre solar farm feeding a data centre under a 25-year power arrangement, targeting $7.3M in annual revenue.
ALPHA COMPUTE (ALP) Buys 300 Acres of Pennsylvania Gas Land for $5.5M
Alpha Compute has signed definitive agreements for Utica and Marcellus acreage with more than 75 wells, and plans to build a data center on the site.
FDA Clears PALISADE BIO IND for PALI-2108 in Crohn's Disease
Palisade Bio can start the Phase 2 ASCENTRA-CD trial of its oral PDE4 prodrug, with first dosing targeted for Q1 2027 and a primary readout in Q1 2028.
PDS (PDSB) BIOTECH Phase 2 Data Published in JAMA Oncology With 39.3-Month Survival
VERSATILE-002 results for PDS0101 plus pembrolizumab show 39.3 months median overall survival in checkpoint-inhibitor-naive HPV16-positive head and neck cancer.